Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Ablynx, Sanofi deal

    Ablynx N.V. (Euronext:ABLX), Ghent, Belgium Sanofi (Euronext:SAN;NYSE:SNY), Paris, France Business: Autoimmune Ablynx and Sanofis Genzyme Corp. unit partnered to exclusively develop Ablynxs Nanobodies against an …

    Published on 5/25/2015
  • Achillion, J&J deal

    Achillion Pharmaceuticals Inc. (NASDAQ:ACHN), New Haven, Conn. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Infectious Achillion granted Johnson & Johnsons Janssen Pharmaceuticals Inc. unit exclusive, …

    Published on 5/25/2015
  • Ambrx, China Everbright, Hopu Investment Management, Shanghai Fosun Pharmaceutical, WuXi PharmaTech deal

    Ambrx Inc., La Jolla, Calif. China Everbright Ltd. (HKSE:165), Hong Kong, China Hopu Investment Management Co. Ltd., Beijing, China Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196;HKSE:2196), Shanghai, …

    Published on 5/25/2015
  • Antares, Medac deal

    Antares Pharma Inc. (NASDAQ:ATRS), Ewing, N.J. Medac GmbH, Wedel, Germany Business: Autoimmune Medacs Medac Pharma subsidiary and Antares granted royalty-free cross-licenses for the U.S. manufacture and sale of Medacs …

    Published on 5/25/2015
  • Antisense Therapeutics, Cortendo deal

    Antisense Therapeutics Ltd. (ASX:ANP), Toorak, Australia Cortendo AB, Trevose, Pa. Business: Endocrine/Metabolic Antisense granted Cortendo exclusive rights to develop and commercialize ATL1103 for endocrinology …

    Published on 5/25/2015
  • ArQule, Beryllium deal

    ArQule Inc. (NASDAQ:ARQL), Woburn, Mass. Beryllium LLC, Bedford, Mass. Business: Cancer ArQule and Beryllium will identify and develop small molecule compounds against PD-1 and PD-L1 using Berylliums drug discovery …

    Published on 5/25/2015
  • Asklepios, Benitec deal

    Asklepios BioPharmaceutical Inc., Chapel Hill, N.C. Benitec Biopharma Ltd. (ASX:BLT), Sydney, Australia Business: Infectious, Gene/Cell therapy Asklepios granted Benitec rights to advanced recombinant adeno-associated …

    Published on 5/25/2015
  • Aspireo, Cortendo deal

    Aspireo Pharmaceuticals Ltd., Tel Aviv, Israel Cortendo AB, Trevose, Pa. Business: Endocrine/Metabolic Cortendo will acquire Somatoprim (DG3173) from Aspireo for $30 million in Cortendo equity. The somatostatin analog …

    Published on 5/25/2015
  • Atlas Genetics deal

    Atlas Genetics Ltd., Trowbridge, U.K. Business: Diagnostic Atlas and an undisclosed pharmaceutical company partnered to develop Atlas io point-of-care infectious disease diagnostic outside of infectious disease. Atlas …

    Published on 5/25/2015
  • BioXcel, Takeda deal

    BioXcel Corp., Branford, Conn. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Other BioXcel and Takedas Takeda Development Center Americas Inc. unit partnered to repurpose Takedas assets for rare …

    Published on 5/25/2015
  • Cancer Research UK, Medivir deal

    Cancer Research UK, London, U.K. Medivir AB (SSE:MVIR B), Huddinge, Sweden Business: Cancer Cancer Research UKs Cancer Research Technology (CRT) Ltd. commercialization and development arm partnered with Medivir to …

    Published on 5/25/2015
  • Cartagenia, Agilent deal

    Cartagenia N.V., Leuven, Belgium Agilent Technologies Inc. (NYSE:A), Santa Clara, Calif. Business: Supply/Service, Genomics Agilent acquired Cartagenia, which focuses on clinical genetics software and database systems. …

    Published on 5/25/2015
  • Entertainment Industry Foundation, Ovarian Cancer Research Fund, Ovarian Cancer National Alliance, National Ovarian Cancer Coalition, AACR deal

    Entertainment Industry Foundation, Los Angeles, Calif. Ovarian Cancer Research Fund, New York, N.Y. Ovarian Cancer National Alliance, Washington, D.C. National Ovarian Cancer Coalition, Dallas, Texas American …

    Published on 5/25/2015
  • Faron Pharmaceuticals, China Medical System deal

    Faron Pharmaceuticals Ltd., Turku, Finland China Medical System Holdings Ltd. (HKSE:867), Shenzhen, China Business: Pulmonary Faron granted China Medical rights in Taiwan and China, including Hong Kong and Macau, to …

    Published on 5/25/2015
  • Genmab, J&J deal

    Genmab A/S (CSE:GEN;OTCBB:GMXAY), Copenhagen, Denmark Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Cancer Genmab will receive a $10 million milestone payment from Johnson & Johnsons Janssen Biotech Inc. …

    Published on 5/25/2015
  • Ikaria, Mallinckrodt deal

    Ikaria Inc., Hampton, N.J. Mallinckrodt plc (NYSE:MNK), St. Louis, Mo. Business: Pulmonary, Hepatic Mallinckrodt completed its acquisition of Ikaria for $2.3 billion from an investor group led by private equity firm …

    Published on 5/25/2015
  • Innate Pharma, Sanofi deal

    Innate Pharma S.A. (Euronext:IPH), Marseille, France Sanofi (Euronext:SAN;NYSE:SNY), Paris, France Business: Cancer, Antibodies Innate will use its site-specific conjugation on Sanofis antibodies to develop antibody-…

    Published on 5/25/2015
  • Innocutis, Cipher deal

    Innocutis Holdings LLC, Charleston, S.C. Cipher Pharmaceuticals Inc. (TSX:DND;NASDAQ:CPHR), Mississauga, Ontario Business: Dermatology Cipher acquired fellow dermatology company Innocutis for $45.5 million in cash. …

    Published on 5/25/2015
  • Intec deal

    Intec Pharma Ltd. (Tel Aviv:INTP), Jerusalem, Israel Business: Drug delivery Intec will apply its Accordian Pill gastro-retentive drug delivery technology to an undisclosed marketed compound from an undisclosed …

    Published on 5/25/2015
  • Merus, Ono Pharmaceutical deal

    Merus B.V., Utrecht, the Netherlands Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Business: Autoimmune, Antibodies Merus received an undisclosed milestone payment as part of an April 2014 deal under which …

    Published on 5/25/2015
  • Multiple Myeloma Research Foundation (MMRF), Amgen, Adaptive Biotechnologies, University of Turin deal

    Multiple Myeloma Research Foundation (MMRF), Norwalk, Conn. Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Adaptive Biotechnologies Corp., Seattle, Wash. University of Turin, Turin, Italy Business: Diagnostic, Cancer …

    Published on 5/25/2015
  • NIH, Compugen deal

    National Institutes of Health, Bethesda, Md. Compugen Ltd. (NASDAQ:CGEN;Tel Aviv:CGEN), Tel Aviv, Israel Business: Cancer The NIH granted Compugen rights to biological systems and materials for advancing Compugens …

    Published on 5/25/2015
  • OncoGenex, Teva deal

    OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI), Bothell, Wash. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Business: Cancer The partners completed the termination of a 2009 deal granting Teva …

    Published on 5/25/2015
  • Pacific Biosciences, RainDance deal

    Pacific Biosciences of California Inc. (NASDAQ:PACB), Menlo Park, Calif. RainDance Technologies Inc., Billerica, Mass. Business: Genomics Pacific Biosciences and RainDance partnered to co-develop and co-commercialize a …

    Published on 5/25/2015
  • Pharmaxis, Boehringer Ingelheim deal

    Pharmaxis Ltd. (ASX:PXS;Pink:PXSLY), Frenchs Forest, Australia Boehringer Ingelheim GmbH, Ingelheim, Germany Business: Hepatic, Inflammation Boehringer exercised its option to acquire worldwide rights to anti-…

    Published on 5/25/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993